notes in Biological Technology
Navigation Links
notes in Biological Technology
ANNAPOLIS, Md., July 31 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP ), a biodefense company developing medical countermeasures against biological and chemical threats, today announced that, effective July 28, 2009, it has closed on the issuance of 2-year, 10% unsecured ...
FRAZER, Pa., May 21 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH ) announced today the pricing of its concurrent public offerings of 5 million shares of common stock, at a price of $60 per share, and $435 million in aggregate principal amount of 2.50% convertible senior subordinated no...
SEATTLE, May 12 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) today announced that it has commenced a "Modified Dutch Auction" tender offer (the "Exchange Offer") to exchange shares of its common stock, no par value ("Common Stock"), and cash for an agg...
VANCOUVER, Aug. 22 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. ("Angiotech") (NASDAQ: ANPI , TSX: ANP), a global specialty pharmaceutical and medical device company, today announced that in connection with the previously announced tender offer (the "Tender Offer") for its outstan...
Investor Also Agrees to Increase Original Warrant Amount by an Additional $44.5 million SEATTLE, July 24 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) today announced that a single institutional investor has agreed to purchase, for $44.5 mi...
VANCOUVER, July 7 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. ("Angiotech") (NASDAQ: ANPI , TSX: ANP), a global specialty pharmaceutical and medical device company, today announced the commencement of a cash tender offer of the outstanding notes listed below (the "Notes") in an a...
SEATTLE, June 12 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) today announced that a single institutional investor has agreed to purchase, for $23 million, newly issued 15% Convertible Senior Notes due 2011, with an initial conversion price of $0.79 per share, and a...
Transaction also provides the Company and investor an option to sell or purchase additional $67.5 million in securities SEATTLE, April 30 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI" or the "Company") (Nasdaq: CTIC ; MTA) today announced that it has entered into agreeme...
CTI Issues approximately 6.85 million shares of Common Stock in Exchange for Senior Subordinated and Subordinated Notes due 2008, plus accrued interest SEATTLE, Feb. 13 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI" or the "Company") (Nasdaq: CTIC ;...
Exchange retired $12.83 million in existing current 2008 convertible notes and extended the maturity to 2011 on an additional $23.25 million in 2008 convertible notes SEATTLE, Dec. 13 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI" or the "Company") (Nasdaq a...
BEDMINSTER, N.J., Oct. 3 /PRNewswire-FirstCall/ -- NPS Pharmaceuticals, Inc. (Nasdaq: NPSP ) announced today that it has amended the terms of its cash tender offer with respect to its outstanding $171.8 million in aggregate principal amount of 3.0 percent convertible notes due 2008. Under the...
PITTSBURGH, Sept. 17 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. (NYSE: MYL ) ("Mylan") announced today certain pricing terms of its previously announced cash tender offers and consent solicitations for its 5.750% Senior Notes due 2010 (CUSIP No. 628530AE7) (the "2010 Notes") and 6.375%...
EMERYVILLE, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced that it has agreed to sell an aggregate of four million shares of its common stock at a price to the public of $30.50 per share and $200 million aggregate principal amou...
SEATTLE, June 2 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (the "Company" or "CTI") (Nasdaq and MTA: CTIC) today announced that it has amended and restated its "Modified Dutch Auction" tender offer to a fixed price tender offer for any and all of the approximately $118.9 million outstanding...
FRAZER, Pa., May 20 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH ) announced today that it intends to offer, subject to market and other conditions, $300 million of common stock and $350 million in aggregate principal amount of convertible senior subordinated notes due 2014 through t...
SEATTLE, May 18 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (the "Company" or "CTI") (Nasdaq and MTA: CTIC) today announced that it has amended its "Modified Dutch Auction" tender offer (the "Exchange Offer") to increase the total consideration of its offer to exchange shares of its common s...
EXTON, Pa., March 24 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM ) announced it has repurchased, in a privately negotiated transaction, $45 million principal amount or 18 percent of the company's Senior Convertible Notes due March 2017 for total consideration of approximately $21.2 mil...
PRINCETON, N.J., March 17 /PRNewswire-FirstCall/ -- PharmaNet Development Group, Inc. (the "Company" , "PDGI" or "PharmaNet") (Nasdaq: PDGI ), a leading provider of clinical development services to innovative pharmaceutical, biotechnology, generic drug and medical device companies, announced tha...
SEATTLE, Dec. 5 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI" or the "Company") (Nasdaq and MTA: CTIC) today announced that a single institutional investor shall purchase, for $32.65 million, newly issued 10% Convertible Senior Notes due 2011 (the "Notes"), with a conversion price of $0...
SEATTLE, Oct. 22 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI" or the "Company") (Nasdaq and MTA: CTIC) today announced that a single institutional investor shall purchase, for $24.7 million, newly issued 9.66% Convertible Senior Notes due 2011, with a conversion price of $0.38 per ...
SEATTLE, Sept. 29 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI" or the "Company") (Nasdaq: CTICD and MTA: CTIC) today announced that a single institutional investor shall purchase, for $14.2 million, newly issued 15.5% Convertible Senior Notes due 2012, with a conversion price of ...
FRAZER, Pa., May 21 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH ) announced today the pricing of its concurrent public offerings of 5 million shares of common stock, at a price of $60 per share, and $435 million in aggregate principal amount of 2.50% convertible senior subordinated no...
Beckman Coulter Prices $500 Million Senior Notes Offering
ORANGE COUNTY, Calif., May 18 /PRNewswire-FirstCall/ -- Beckman Coulter, Inc. (NYSE: BEC ), a leading developer, manufacturer and marketer of products that simplify, automate and innovate complex biomedical testing, announced today the pricing of its senior notes offering of: ...SEATTLE, May 12 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) today announced that it has commenced a "Modified Dutch Auction" tender offer (the "Exchange Offer") to exchange shares of its common stock, no par value ("Common Stock"), and cash for an agg...
VANCOUVER, Aug. 22 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. ("Angiotech") (NASDAQ: ANPI , TSX: ANP), a global specialty pharmaceutical and medical device company, today announced that in connection with the previously announced tender offer (the "Tender Offer") for its outstan...
Investor Also Agrees to Increase Original Warrant Amount by an Additional $44.5 million SEATTLE, July 24 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) today announced that a single institutional investor has agreed to purchase, for $44.5 mi...
VANCOUVER, July 7 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. ("Angiotech") (NASDAQ: ANPI , TSX: ANP), a global specialty pharmaceutical and medical device company, today announced the commencement of a cash tender offer of the outstanding notes listed below (the "Notes") in an a...
SEATTLE, June 12 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) today announced that a single institutional investor has agreed to purchase, for $23 million, newly issued 15% Convertible Senior Notes due 2011, with an initial conversion price of $0.79 per share, and a...
Transaction also provides the Company and investor an option to sell or purchase additional $67.5 million in securities SEATTLE, April 30 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI" or the "Company") (Nasdaq: CTIC ; MTA) today announced that it has entered into agreeme...
CTI Issues approximately 6.85 million shares of Common Stock in Exchange for Senior Subordinated and Subordinated Notes due 2008, plus accrued interest SEATTLE, Feb. 13 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI" or the "Company") (Nasdaq: CTIC ;...
Exchange retired $12.83 million in existing current 2008 convertible notes and extended the maturity to 2011 on an additional $23.25 million in 2008 convertible notes SEATTLE, Dec. 13 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI" or the "Company") (Nasdaq a...
BEDMINSTER, N.J., Oct. 3 /PRNewswire-FirstCall/ -- NPS Pharmaceuticals, Inc. (Nasdaq: NPSP ) announced today that it has amended the terms of its cash tender offer with respect to its outstanding $171.8 million in aggregate principal amount of 3.0 percent convertible notes due 2008. Under the...
PITTSBURGH, Sept. 17 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. (NYSE: MYL ) ("Mylan") announced today certain pricing terms of its previously announced cash tender offers and consent solicitations for its 5.750% Senior Notes due 2010 (CUSIP No. 628530AE7) (the "2010 Notes") and 6.375%...
Schering-Plough Announces Pricing of Senior Notes Offering
KENILWORTH, N.J., Sept. 12 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ) announced today that it has agreed to sell $1 billion aggregate principal amount of 6.00% Senior Notes due 2017 and $1 billion aggregate principal amount of 6.55% Senior Notes due 2037 through an und...NPS Pharmaceuticals Commences Tender Offer for 3.0% Convertible Notes Due 2008
PARSIPPANY, N.J., Sept. 6 /PRNewswire-FirstCall/ -- NPS Pharmaceuticals, Inc. (Nasdaq: NPSP ) announced today that it has commenced a cash tender offer for any and all of its outstanding 3.0% Convertible Notes due 2008. The tender offer will expire at midnight, Eastern Time on October 4, 2007...Avitar's Notes Significance of New On-Site Oral Fluid Drug Testing Laws
Drug Free Workplace Programs To Become More Effective, Widespread CANTON, Mass., Aug. 15 /PRNewswire-FirstCall/ -- Avitar, Inc. (OTC Bulletin Board: AVTI) highlights the importance of the State of Hawaii's recent updating of their workplace drug testing laws to incorporate oral fluid-based ...EMERYVILLE, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced that it has agreed to sell an aggregate of four million shares of its common stock at a price to the public of $30.50 per share and $200 million aggregate principal amou...
Verenium Completes Amendment to 8% Senior Convertible Notes
CAMBRIDGE, Mass., July 6 /PRNewswire-FirstCall/ -- Verenium Corporation (Nasdaq: VRNM ) announced today that the agreement to amend the $29.5 million of outstanding 8% Senior Convertible Notes due April 1, 2012 (the "Notes") entered into and announced on July 1, 2009 is effective as of 8:00 a....SEATTLE, June 2 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (the "Company" or "CTI") (Nasdaq and MTA: CTIC) today announced that it has amended and restated its "Modified Dutch Auction" tender offer to a fixed price tender offer for any and all of the approximately $118.9 million outstanding...
FRAZER, Pa., May 20 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH ) announced today that it intends to offer, subject to market and other conditions, $300 million of common stock and $350 million in aggregate principal amount of convertible senior subordinated notes due 2014 through t...
SEATTLE, May 18 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (the "Company" or "CTI") (Nasdaq and MTA: CTIC) today announced that it has amended its "Modified Dutch Auction" tender offer (the "Exchange Offer") to increase the total consideration of its offer to exchange shares of its common s...
deCODE to Utilize Grace Period for Interest Payment on Senior Convertible Notes
REYKJAVIK, Iceland, April 15 /PRNewswire-FirstCall/ -- deCODE genetics (Nasdaq: DCGN ) today announced that in order to provide more time for the execution of strategic alternatives currently under consideration, it has elected to utilize a 30-day grace period for the scheduled April 15 inter...EXTON, Pa., March 24 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM ) announced it has repurchased, in a privately negotiated transaction, $45 million principal amount or 18 percent of the company's Senior Convertible Notes due March 2017 for total consideration of approximately $21.2 mil...
PRINCETON, N.J., March 17 /PRNewswire-FirstCall/ -- PharmaNet Development Group, Inc. (the "Company" , "PDGI" or "PharmaNet") (Nasdaq: PDGI ), a leading provider of clinical development services to innovative pharmaceutical, biotechnology, generic drug and medical device companies, announced tha...
SEATTLE, Dec. 5 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI" or the "Company") (Nasdaq and MTA: CTIC) today announced that a single institutional investor shall purchase, for $32.65 million, newly issued 10% Convertible Senior Notes due 2011 (the "Notes"), with a conversion price of $0...
SEATTLE, Oct. 22 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI" or the "Company") (Nasdaq and MTA: CTIC) today announced that a single institutional investor shall purchase, for $24.7 million, newly issued 9.66% Convertible Senior Notes due 2011, with a conversion price of $0.38 per ...
Acasti Pharma completes offer to exchange outstanding Neptune Technologies dividend notes
LAVAL, QC, Oct. 21 /PRNewswire-FirstCall/ - Acasti Pharma Inc., a pharmaceutical subsidiary of Neptune Technologies & Bioressources Inc. ("Neptune") (NASDAQ.NEPT - TSX.V.NTB) today announced that it has acquired a majority of the 9,380,355 non-convertible notes issued by Neptune on August 11, ...SEATTLE, Sept. 29 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI" or the "Company") (Nasdaq: CTICD and MTA: CTIC) today announced that a single institutional investor shall purchase, for $14.2 million, newly issued 15.5% Convertible Senior Notes due 2012, with a conversion price of ...
AMDL, Inc. Closes Private Placement of Convertible Notes
TUSTIN, Calif., Sept. 16 /PRNewswire-FirstCall/ -- ( http://www.amdl.com ) AMDL, Inc. (Amex: ADL ), a vertically integrated pharmaceutical company with major operations in China and the US, announced today the successful closing and terms of a $2,510,000 private placement offering of 10% conv...Indevus Announces Private Placement of $105 Million of Non-Recourse Notes
Notes Secured by Royalties on U.S. Sales of SANCTURA(R) and SANCTURA XR(TM) LEXINGTON, Mass., Aug. 26 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV ) announced today that it has closed a private placement to institutional investors of $105.0 million of non-recourse notes...China Medical Technologies Adjusts Conversion Rate of Convertible Notes
BEIJING, July 25 /Xinhua-PRNewswire-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED ), a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic products and high intensity focused ultrasound tumor therapy sy...American Oriental Bioengineering Proposes Offering of $85 Million of Convertible Notes
NEW YORK, July 7 /PRNewswire-FirstCall/ -- American Oriental Bioengineering, Inc. (NYSE: AOB ) today announced its intention to offer, subject to market conditions and other factors, $85 million aggregate principal amount of Convertible Senior Notes due 2015 to qualified institutional buyers ...Bristol-Myers Squibb Issues $1.6 Billion of Senior Notes
NEW YORK, April 29 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE: BMY ) announced today that it has agreed to sell $1.6 billion of senior unsecured notes: $600 million in aggregate principal amount of 5.450% notes due May 1, 2018 and $1 billion in aggregate principal amount of ...Medco Issues $1.5 Billion of Senior Notes
FRANKLIN LAKES, N.J., March 13 /PRNewswire-FirstCall/ -- Medco Health Solutions, Inc. (NYSE: MHS ) announced today that it has agreed to sell $300 million aggregate principal amount of 6-1/8 percent senior notes due March 15, 2013 and $1.2 billion aggregate principal amount of 7-1/8 percent s...Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
NEW HAVEN, Conn., Feb. 15 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VION ) today announced that the Company had paid interest due February 15, 2008 on its 7.75% Convertible Senior Notes due 2012 (the "Notes"). The aggregate principal amount of the Notes is $60 million. T...USGI Medical Demonstrates First System for Gastrotomy Closure in NOTES
Gastrotomy Closure Considered Largest Hurdle in Adoption of Incisionless Natural Orifice Translumenal Endoscopic Surgery (NOTES) SAN CLEMENTE, Calif., Dec. 19 /PRNewswire/ -- USGI Medical, Inc., the leader in the emerging field of Incisionless Surgery, today announced that its EndoSurgi...Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
NEW HAVEN, Conn., Aug. 15 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VION ) today announced that the Company had paid interest due August 15, 2007 on its 7.75% Convertible Senior Notes due 2012 (the "Notes"). The aggregate principal amount of the Notes is $60 million. The ...General Notes on Primer Design in PCR*
Vincent R. Prezioso, PhD BioSystems Laboratory, Brinkmann Instruments Inc., Westbury, New York Perhaps the most critical parameter for successful PCR is the design of Primers. All t...Eppendorf Electroporation Application Notes Your participation is highly welcome !!!
E-mail us your application notes for inclusion in this Eppendorf web page. Each contribution published will be acknowledged with a set of electroporation cuvettes. Protocols for Bacteria, Y...Eppendorf Electroporation Application Notes Your participation is highly welcome !!!
E-mail us your application notes for inclusion in this Eppendorf web page. Each contribution published will be acknowledged with a set of electroporation cuvettes. Protocols for Bacteria, Y...Other TagsMedicinalAlertAlertAthleticSurgeSurgeSurgeSurgeSurgeSurgeOther Contentsdissectiondissectiondissectiondissectionapathyapathyaphasiaaphthousaplasticappendicitisareola
TastyDermatologistsMedicinalPessimisticAlertActonelIslamabadMisledBombayScinetistsAthleticAverageWaltzSurge
(Date:11/26/2009)..., Heidelberg, 27 November 2009 What are the bare... required to produce a cell that can survive on it...cell, and understand how an entire organism functi...ons that scientists in a partnership between the E...delberg, Germany, and the Centre de Regulacio Genm...
(Date:11/25/2009)...hrelin, a hormone produced in the stomach, may be ...ent of Parkinson,s disease, Yale School of Medicin...ent issue of the Journal of Neuroscience . , Pa...opamine neurons in an area of the midbrain known a...opamine production. Reduced production of dopamin...
(Date:11/25/2009)... Dr. Sarit Larisch, Head of the Cell Death Researc...nt of Biology, has been awarded the prestigious Jo...arch exploring the cause of brain cell damage in P...ch year to scientists in support of innovation and... officially conferred earlier this month at an eve...
Breaking Biology News(10 mins):First-ever blueprint of a minimal cell is more complex than expected 2First-ever blueprint of a minimal cell is more complex than expected 3Hormone ghrelin can boost resistance to Parkinson's disease 2Johnson & Johnson award goes to research of the cause of brain cell damage in Parkinson's 2Carnitine supplements reverse glucose intolerance in animals 9553 1Carnitine supplements reverse glucose intolerance in animals 9553 2New insights into limb formation 9549 1New insights into limb formation 9549 2Lumension Expands Global Footprint and Strengthens Capabilities with the Opening of a New Development Office in Ireland 54355 1Lumension Expands Global Footprint and Strengthens Capabilities with the Opening of a New Development Office in Ireland 54355 2Lumension Expands Global Footprint and Strengthens Capabilities with the Opening of a New Development Office in Ireland 54355 3(Date:11/27/2009)... Specialist manufacturers who u...ts are saving millions of dollars by bringing in t...ess. Increasing numbers of pro-active medical manu... at the concept stage of their projects, ensuring ...design processes or potentially outdated technolog...
(Date:11/26/2009)... , PRINCETON, N.J., Nov. 27 T...lmost double over the next 25 years and annual med...336 billion, up from $113 billion today, according...abetes Care . The National Changing Diabetes ...missioned the analysis by a team from the Universi...
(Date:11/26/2009)...e that,s too big or too heavy can lead to strains ...y News) -- There may be nothing wrong with stuffin...want to do the same thing with your suitcase as yo...ople were treated in 2008 in U.S. hospital emergen...cal facilities for luggage-related injuries, such ...
(Date:11/26/2009)... Dr. David Kim of the Live Life...rgery in Dallas , is one of a growing number of ph...al networking sites to connect with individuals wh... to fight morbid obesity. Dr. Kim is utilizing Fac...tion about his practice with the community. , ...
(Date:11/26/2009)... Ennis & Ennis, P.A. is off...or users of Yaz and Yasmin birth control pills who...nary Embolism, Stroke, Heart Attack or other relat.... Women can call toll free at 1-800-856-6405 or go...aw.com and fill out an online case evaluation for...
Breaking Medicine News(10 mins):Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 2Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 3Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 4Health News:Pack Right for the Holidays to Avoid the ER 2Health News:Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients 2Health News:Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients 3Health News:Ennis & Ennis, P.A. Announces Nationwide Free, Confidential, Consultations For Users Of Yaz And Yasmin Birth Control Pills 2Health News:Ennis & Ennis, P.A. Announces Nationwide Free, Confidential, Consultations For Users Of Yaz And Yasmin Birth Control Pills 3[0] Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells[1] Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows[2] Pack Right for the Holidays to Avoid the ER[1] Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients[0] Ennis & Ennis, P.A. Announces Nationwide Free, Confidential, Consultations For Users Of Yaz And Yasmin Birth Control Pills
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |